Abstract
efflux). Where indicated, 10% FBS or 100% pooled human serum (Sigma; St. Louis, MO) was 151 added to the incubation media. Cells were incubated at 37ºC for 90 minutes. At the end of the 152 incubation, the cells were washed 3 times with ice-cold PBS (2 mL/well) and lysed directly on 153 the plate by adding 0.4% Triton X-100 (1 mL/well) for 15 minutes. The intracellular level of 3 H - were then overlayed onto pre-prepared microcentrifuge tubes containing 100 μL 2N NaOH
182
(bottom layer) and100 μL filtration oil (top layer; 74.5:25.5 silicon oil:mineral oil mix). Samples
183
were centrifuged immediately at 13,600 x g for 30 seconds to pellet the cells. The samples were 184 then allowed to sit at room temperature for 2 hours to complete cell lysis and frozen for at least 1 elvitegravir or emtricitabine. The final amount of DMSO was maintained at 1% across the plate.
235
The concentrations used in combination with TFV corresponded to their respective peak plasma 236 levels in treated HIV-infected patients. Cells were incubated at 37ºC in a humidified chamber 237 with 5% CO 2 . After 4 days, the cell viability was determined by the addition of 100 μL CellTiter OATs.
255
COBI at concentrations ranging from 0.5 to 15 μM was tested for an effect on the active was only weakly affected in the presence of COBI at the highest tested concentration (15 μM).
TFV uptake to an equal or lesser degree compared to RTV. While not predicted to have any 410 effect at pharmacologically relevant concentrations, it is important to note that the inhibition of
411
TFV uptake would decrease intracellular levels of TFV in the proximal tubule.
412
The present study also assessed the effect of COBI and the combination of COBI,
413
elvitegravir and emtricitabine on the cytotoxicity of TFV in two in vitro renal cell culture 
